This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ETF Industry to Get a Product on Marijuana?
by Sanghamitra Saha
A new fund has been filed targeting the medical marijuana industry.
Biotech ETFs Powered by Q4 Earnings
by Sweta Killa
Improved earnings are driving the biotech space and ETFs higher over the past 10 days.
Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead
by Zacks Equity Research
Zacks Market Edge Highlights: Health Care SPDR ETF, iShares NASDAQ Biotechnology ETF, Acadia, Aetna and Gilead
Healthcare Stocks: The Buying Opportunity of the Year?
by Tracey Ryniec
Tracey and Kevin discuss whether healthcare stocks are still the ???sure things??? they???ve been the last 10 years.
Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting
by Madeleine Johnson
Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.
What Lies Ahead for Biotech ETFs in Trump Era?
by Zacks Equity Research
Despite political risks, there are many factors supporting growth in the biotech sector.
4 Top Biotech Mutual Funds for 2017
by Zacks Equity Research
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.
Biotech & Pharma ETFs to Suffer in 2017 Too?
by Sanghamitra Saha
What lies ahead for biotech and pharma ETFs in 2017?
Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower
by Ryan McQueeney
Shares of the iShares Nasdaq Biotechnology ETF (IBB) are down more than 3.6% in morning trading Wednesday following a new warning from President-elect Donald Trump that he will indeed be targeting high drug prices.
5 Top-Ranked Sector ETFs Thankful to Trump
by Sanghamitra Saha
These sector ETFs scooped up strong gains on Trump's victory and were upgraded to the Buy or Strong Buy list by the Zacks methodology.
Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?
by Eric Dutram
In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.
4 Best Healthcare Mutual Funds to Profit from Trump Win
by Zacks Equity Research
Donald Trump's win has had a substantial positive impact on the pharmaceutical industry
What Investors Need to Know About Biotech ETF Investing
by Eric Dutram
Taking a look at 3 key factors to evaluate when you are considering a biotech ETF.
How to Invest in Leveraged Biotechnology ETFs
by Eric Dutram
What investors need to know about leveraged and inverse biotechnology ETF investing.